91爆料

October 10

Ozempic and similar drugs could interfere with common medical procedure, research warns

A new study reveals that GLP-1 drugs may affect medical scan results, though experts say findings are preliminary and more data is needed before changing medical practice.

October 7

Experts sound alarm as weight-loss shortcut could put Americans at risk

High costs and shortages are driving demand for unregulated GLP-1 drugs, prompting FDA alerts about counterfeit Ozempic and calls for stricter enforcement by legal experts.

October 2

Weight-loss surgery pros and cons in the spotlight after singer's 'scary' experience

Weight-loss experts explain why combining GLP-1 medications with bariatric surgery may be the most effective approach to treating obesity in 2025.

September 29

Weight-loss drugs now linked to cancer protection in women, major new study reveals

A new study finds that GLP-1 medications are linked to lower overall cancer risk, particularly for endometrial and ovarian cancers, in obese adults. Oncologist Dr. Slomovitz discusses the findings.

September 28

Oncology director shares how GLP-1s can help protect against cancer

Dr. Brian Slomovitz, director of gynecologic oncology at Mount Sinai Medical Center in Miami Beach, Florida, says the link between GLP-1 and reduced cancer risk is "not surprising."

September 25

Weight-loss doctor shares how GLP-1s could rewire body against disease

New York City doctors reveals how weight-loss drugs reduce inflammatory cytokines by decreasing fat cells, potentially preventing cancer and autoimmune diseases.

September 24

Weight loss drugs show promise in reducing inflammation beyond fat burning, doctor says

Dr. Sue Decotiis, a New York City weight loss physician, discusses how GLP-1s impact inflammation, relieving conditions from arthritis to cancer.

September 23

No more injections? New pill could replace Ozempic and Wegovy for weight loss

A new oral weight loss medication, orforglipron, demonstrated meaningful weight loss results in phase 3 trials, potentially providing an easier alternative to Ozempic injections.

September 21

Dan Marino鈥檚 metabolic liver disease highlights growing health concern

Metabolic dysfunction-associated steatohepatitis (MASH) is a silent liver disease that is caused by fat buildup, inflammation and cell damage in the liver. Here's what to know.

September 20

Researchers say being 'fat but fit' could be less deadly than being underweight

New research challenges BMI assumptions, showing overweight individuals may not face higher death rates while underweight people show increased mortality risk.